Ongoing and New Business

CTAC November 10, 2021

2

Topics

1. CTAC Member Recognition – Dr. Debra Barton

2. CTAC Group Updates

▪ Gastric and Esophageal Cancers Working Group

▪ Glioblastoma Working Group

3. Announcements

3

CTAC Member Recognition

Debra L. Barton, Ph.D., R.N., F.A.A.N.

5

CTAC Group Updates

6

CTAC Translational Research Working Groups

Translational Research Strategy Subcommittee (TRSS)

Co-Chairs: Chi Dang, M.D., Ph.D.

Nancy Davidson, M.D.

Glioblastoma

Working Group (2019)

Co-Chairs:

Walter Curran, Jr., M.D.

Chi Dang, M.D., Ph.D.

Radiation Oncology

Working Group (2020)

Co-Chairs:

Adam Dicker, M.D., Ph.D.

Silvia Formenti, M.D.

Gastric and Esophageal Cancers Working Group

Co-Chairs:

Karyn Goodman, M.D.

Anil Rustgi, M.D.

GBM Report: https://deainfo.nci.nih.gov/advisory/ctac/0719/Att_12_GBM%20WG%20Final%20Report%20CTAC%207-17-19_v1.pdfRad Onc Report: https://deainfo.nci.nih.gov/advisory/ctac/1120/RadOncWGreport.pdf

7

Gastric and Esophageal Cancers Working Group

Co-chairs:

▪ Karyn Goodman, M.D., M.S., Mount Sinai, New York, NY

▪ Anil Rustgi, M.D., Columbia University Herbert Irving

Comprehensive Cancer Center, New York, NY

First Working Group meeting:

▪ Monday, December 13, 2021

8

Glioblastoma Therapeutics Network (GTN)

▪ RFA concept approved by the Board of Scientific Advisors in May 2020

▪ Purpose of the RFA: improve the treatment of adult GBM by

developing novel effective agents and testing them in the clinic

▪ Overall goal: to develop novel agents for treatment of GBM and test

in human pilot PD studies

• Focus on late Drug Discovery through Phase I clinical studies

• Possible agents include small molecules, biologics, and/or radiotherapy

• Testing in animal models that closely mimic human adult GBM

• Aim for early-phase proof-of-mechanism clinical trials that include PK, PD,

and imaging

9

Glioblastoma Therapeutics Network (GTN)

Project 2

Project 1

Admin Core

Project 3

Project 2

Project 1

Admin Core

Core 2

Core 1

Project 2

Project 1

Admin Core

Core 1

Core 2Core 1

Project 3

Project 2

Project 1

Admin Core

Core 1

Project 2

Project 1

Admin Core

Core 1

Steering Committee

Trans-U19 activities

U19 Center

NCC – U19 interaction

Sarkaria, Galanis (Mayo

Rochester); Bindra, Omuro (Yale)

“Center of Innovation for Brain Tumor

Therapeutics”

Batchelor (Brigham & Women’s)

“Harvard/Stanford GTN Program: Novel

targeted therapeutics for glioblastoma”

Portnow & Badie (City of Hope)

“Development of Small Molecule Inhibitors

and Biologic Agents for Treatment of Glioblastoma Using Intracerebral

Microdialysis and Signatures of Vulnerability”

Ashley (Duke); Shay (UTSW)

“6-thio-2-deoxyguanosine: A Novel

Immunogenic Telomerase-Mediated

Therapy in Glioblastoma - A Duke

and UTSW Collaboration”

Butowski (UCSF);

Stupp (Northwestern)

“Advancing treatment and

understanding of immunotherapy in

glioblastoma”

https://dctd.cancer.gov/NewsEvents/20210928_glioblastoma_therapeutics_network.htm

10

Announcements

11

Announcements

▪ Next CTAC Meeting

• Wednesday, March 16, 2022 – Planned to be virtual at this time

▪ Federal COVID-19 Vaccination Mandate

• All CTAC members (Special Government Employees) are required to

comply with the federal COVID-19 vaccination mandate prior to the next

CTAC meeting.

• Watch for an NIH Secure email from Ms. Christine Skeens providing you

with the necessary information to complete the vaccination verification

form.

www.cancer.gov www.cancer.gov/espanol